Literature DB >> 16376131

PMM2 intronic branch-site mutations in CDG-Ia.

Sandrine Vuillaumier-Barrot1, Christiane Le Bizec, Pascale De Lonlay, Nathalie Madinier-Chappat, Anne Barnier, Thierry Dupré, Geneviève Durand, Nathalie Seta.   

Abstract

Congenital Disorders of Glycosylation (CDG, OMIM#212065)-Ia is an autosomal recessive disorder, characterized by central nervous system dysfunction and multiorgan failure associated with mutations in the PMM2 gene. We report two patients who are compound heterozygotes with respect to two new intronic mutations that affect a highly conserved adenosine in a consensus branch-site sequence. The mutations, one in intron 7: c.340 -23A > G (IVS7 -23A > G) and the other in intron 2: c.179 -25A > G (IVS2 -25A > G), are associated with the c.422G > A (R141H) and c.193 G > T (D65Y) mutations, respectively. The c.179 -25A > G and the c.340 -23A > G changes cause exon 3 and exon 8 to be lost at the RNA level, respectively. This kind of mutation can cause a problem in molecular diagnosis of CDG-Ia if intronic primers are not correctly chosen, and if molecular diagnosis is not performed at both the DNA and mRNA levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376131     DOI: 10.1016/j.ymgme.2005.10.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  Human genetic variation recognizes functional elements in noncoding sequence.

Authors:  David Lomelin; Eric Jorgenson; Neil Risch
Journal:  Genome Res       Date:  2009-12-23       Impact factor: 9.043

Review 2.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

3.  Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypes.

Authors:  Guillaume Dorval; Cécile Jeanpierre; Vincent Morinière; Carole Tournant; Bettina Bessières; Tania Attié-Bittach; Jeanne Amiel; Emmanuel Spaggari; Yves Ville; Elodie Merieau; Marie-Claire Gubler; Sophie Saunier; Laurence Heidet
Journal:  Pediatr Nephrol       Date:  2021-02-13       Impact factor: 3.714

Review 4.  CDG Therapies: From Bench to Bedside.

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

5.  Non-functional alternative splicing caused by a Latino pathogenic variant in a case of PMM2-CDG.

Authors:  C A González-Domínguez; C E Villarroel; M Rodríguez-Morales; S Manrique-Hernández; A González-Jaimes; F Olvera-Rodriguez; K Beutelspacher; C Molina-Garay; K Carrillo-Sánchez; L L Flores-Lagunes; M Jiménez-Olivares; A Muñoz-Rivas; M E Cruz-Muñoz; H M Mora-Montes; R Salinas-Marín; C Alaez-Verson; I Martínez-Duncker
Journal:  Mol Genet Metab Rep       Date:  2021-07-02

6.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals.

Authors:  François-Olivier Desmet; Dalil Hamroun; Marine Lalande; Gwenaëlle Collod-Béroud; Mireille Claustres; Christophe Béroud
Journal:  Nucleic Acids Res       Date:  2009-04-01       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.